CLL

expert roundtables

by Matthew S. Davids, MD, MMSc; and Susan O'Brien, MD

The selection of therapy for older patients with chronic lymphocytic leukemia (CLL) requires a careful consideration of fitness and preexisting com......READ MORE

expert roundtables

by Matthew S. Davids, MD, MMSc; and Susan O'Brien, MD

Novel agents are well established in relapsed and refractory chronic lymphocytic leukemia (CLL), and they have largely replaced chemoimmunotherapy ......READ MORE

patient care perspectives

by Susan O’Brien, MD

There is no geriatric assessment tool to determine whether an older frail patient with chronic lymphocytic leukemia (CLL) is best suited for one sp......READ MORE

patient care perspectives

by Matthew S. Davids, MD, MMSc

Vaccine responses are generally reduced in patients with chronic lymphocytic leukemia (CLL). Nonetheless, vaccination remains an important part of ......READ MORE

clinical topic updates

by Matthew S. Davids, MD, MMSc

The biology of Richter’s syndrome (RS) is not as well understood as that of chronic lymphocytic leukemia (CLL), but there has been some progress in......READ MORE